P. Smirnov

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

S. Chimenti, J. Lambert, T. Luger, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

FRI0436 ACHIEVING THE TREATMENT TARGETS OF REMISSION OR LOW DISEASE ACTIVITY (LDA) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED QUALITY OF LIFE, FUNCTION AND PAIN

E. Theander, P. Sfikakis, S. Siebert, 2019, Psoriatic arthritis.

245 Remission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors

E. Theander, P. Sfikakis, S. Siebert, 2019, Rheumatology.

AB0928 Ustekinumab and tnf inhibitors in psoriatic arthritis: first follow-up data from a routine care study in 8 european countries (PSABIO)

E. Theander, P. Sfikakis, S. Siebert, 2018, Psoriatic arthritis.

Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

G. Girolomoni, F. Sampogna, P. Bergmans, 2017, The British journal of dermatology.

Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO

G. Girolomoni, F. Sampogna, P. Bergmans, 2018, The British journal of dermatology.